A randomized phase III study comparing induction chemotherapy to daily low dose Cisplatin both combined with high dose radiotherapy in patients with inoperable non-small cell lung cancer stage I, II and III.

1. Pathologically confirmed Non-small cell lung cancer;

2. Medically inoperable or irresectable NSCLC T 1-4, N0-3, M0;

3. Age >18 yr;

4. Weight loss < 10% in the last 3 months;

5. FeV1>0.99l, TLCO> 59%.

1. Previous chemotherapy and/or radiotherapy of the chest;

2. Superior Vena cava syndrome;

3. Hemoptysis causing a decrease of the blood haemoglobin of > 1 mmol/L within 24 hours;

4. Pleural or pericardial effusion (except if negative cytology);

5. Uncontrolled infection;

6. Maximal length of the esophagus receiving 40 Gy of more than 18 cm, or maximal length of the esophagus receiving 66 Gy of more than 12 cm;

7. Serious medical risk factors involving any of the major organ systems which may prevent adherence to the treatment schedule;

8. Patients with pre-existant fibrotic lung disease;

9. Creatinin clearance <70 ml/min or creatinin > 1.25 x normal value;

10. Bone marrow hypoplasia(Hb,6.8mmol/l, WBC,4x10 9 /l, platelets,100x10 9/l;

11. Recent myocardial infarction(<6 months) or evidence of heart failure;

12. Impossibility to limit the spinal cord dose to a maximum of 50Gy;

13. Impossibility to exclude 2/3 of the heart from the boost volume.